静脉注射剂说明书给药途径描述的分析

doi:10.19803/j.1672-8629.2021.09.16

中国药物警戒 ›› 2021, Vol. 18 ›› Issue (9): 872-875.
DOI: 10.19803/j.1672-8629.2021.09.16

静脉注射剂说明书给药途径描述的分析

罗一冲¹, 蔡丽萍^2,*, 普燕芳³, 赵锦华¹

¹云南省弥勒第一医院药剂科,云南红河 652399;
²云南省药品监督管理局,云南昆明 650106;
³云南省第一人民医院药学部,云南昆明 650032

收稿日期:2019-12-10 出版日期:2021-09-15 发布日期:2021-09-18
通讯作者: ^*蔡丽萍,女,本科,药事管理。E-mail：2092776621@qq.com
作者简介:罗一冲,男,本科,副主任药师,药事管理/临床药学。

Routes of Administration Described in Specifications of 236 Types of Intravenous Injections

LUO Yichong¹, CAI Liping^2,*, PU Yanfang³, ZHAO Jinhua¹

¹Department of Pharmacy, the First Hospital of Mile City, Mile Yunnan 652399, China;
²Medical Products Administration of Yunnan Province, Kunming Yunnan 650106, China;
³Department of Pharmacy, the First People's Hospital of Yunnan Province, Kunming Yunnan 650032, China

Received:2019-12-10 Online:2021-09-15 Published:2021-09-18

摘要/Abstract

摘要： 目的分析静脉注射剂说明书中给药途径的描述,为临床合理开具给药方法提供参考。方法统计分析236种静脉注射剂说明书中的给药方法,探讨静脉注射剂给药方法描述的差异。结果 236种静脉注射剂说明书中对给药途径描述不规范的有11种（4.7%）,静脉注射和静脉滴注概念不清。结论静脉注射剂说明书中对给药途径描述不规范性问题,亟待生产企业和药品监管部门进一步规范。

关键词: 静脉注射剂, 说明书, 给药方法, 调查分析

Abstract: Objective To investigate how routes of administration are described in the specifications of intravenous injections in order to provide reference for clinical rational drug use and prevent off-label use of medicines. Methods The routes of administration of 236 types of intravenous injections described in the specifications were statistically analyzed, and the difference in the descriptions of how these intravenous injections were administered was studied. Results The descriptions about routes of administration of eleven of these intravenous injections were non-standard in the specifications (4.7%), and intravenous injection and intravenous infusion were not clearly defined. Conclusion Non-standard descriptions of routes of administration in the specifications of intravenous injections are an urgent issue to be addressed by enterprises and related departments of the National Medical Products Administration.

Key words: intravenous injections, specification, medication, investigation and analysis

中图分类号:

R969.3

罗一冲, 蔡丽萍, 普燕芳, 赵锦华. 静脉注射剂说明书给药途径描述的分析[J]. 中国药物警戒, 2021, 18(9): 872-875.

LUO Yichong, CAI Liping, PU Yanfang, ZHAO Jinhua. Routes of Administration Described in Specifications of 236 Types of Intravenous Injections[J]. Chinese Journal of Pharmacovigilance, 2021, 18(9): 872-875.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.2021.09.16

https://zgywjj.magtechjournal.com/CN/Y2021/V18/I9/872

参考文献

[1] Cui FD.Pharmacy, Version 2.(药剂学)[M]. Beijing: China Medical Science and Technology Press, 2011: 207-209.
[2] National Medical Products Administration. Administrative regulat-ions of dispensatory and labels(药品说明书和标签管理规定)[S]. National Medical Products Administration, 2006.
[3] National Medical Products Administration. Notice on the issuance of Writing Requirements and Guiding Principles for the Format and Content of Prescription Manual of Traditional Chinese Medicine and Natural Medicine(关于印发中药、天然药物处方药说明书格式内容书写要求及撰写指导原则的通知)[S]. National Medical Products Administration, 2006.
[4] National Medical Products Administration.Notice on the issuance of detailed terms for the dispensatory of chemical drugs and biological products(关于印发化学药品和生物制品说明书规范细则的通知)[S]. National Medical Products Administration, 2006.
[5] Chinese Pharmacopoeia Commission.Pharmacopoeia of the People’s Republic of China(中华人民共和国药典)[S]. Beijing: China Medical Science and Technology Press, 2020.
[6] Zhang Q, Wu YZ, Fu H, et al.stability study on omeprazole sodium for injection in two different administration methods[J]. Chinese Journal of Modern Applied Pharmacy(中国现代应用药学), 2018,35(11): 1652-1655.
[7] China Health Promotion Foundation, Chinese Pharmacists Association, China National Pharmaceutical Packaging Association, et al. Protect the safety on the tip of the needle-the consensus of experts on Chinese transfusion safety and protection[J] Drug Evaluation(药品评价), 2016, 13(10): 8-17.
[8] Zhang JS, Qi Y, Wang XL, et al.stability study on compatibility of omeprazole solution for injection[J]. China Pharmacist(中国药师), 2007, 10(4): 352-354.
[9] National Medical Products Administration.Adverse reaction information notification(38)Be alert to severe allergic reaction of asarum cerebral injection[DB/OL].(2011-06-10)[2019-11-20]. http://www.nmpa.gov.cn/WS04/CL2155/318854.html .
[10] National Medical Products Administration. Notice of General Office of the National Medical Products Administration on Revising the Dispensatory of Asarum Cerebral Injection[S]. Food and Drug Administration (drug chemical tube), 2014. No. 78.
[11] Wang YL, Investigation and analysis of 40 groups of injection instructions in our hospital[J]. Chinese Journal of Pharmacovigilance(中国药物警戒)2018, 15(3): 147-151, 168.
[12] Hu X, Zhang YM, Liu X, et al.Investigation and suggestions on the labelling of 75 intravenous antiinfective drugs instructions[J].Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(3): 68-170.
[13] Li MJ, Shi TL, Zhang ZT.An analysis of 170 intravenous drug delivery routes[J]Evaluation and Analysis of Drug-Use in Hospitals of China(中国医院用药评价与分析), 2017, 17(10): 1408-1410.

[1]	王春婷, 陈亚飞, 李婷婷. 化学药品上市后说明书安全信息修订考虑要点[J]. 中国药物警戒, 2025, 22(7): 776-779.
[2]	邹远磊, 夏清荣, 梁俊, 何孔亮, 莫大明, 吴文宁. 抗抑郁药说明书警示语及预防措施分析[J]. 中国药物警戒, 2025, 22(3): 329-333.
[3]	朱兰, 邵波, 朱彦, 戴洁, 钟诗琦. 已上市中成药说明书安全信息修订实践与思考[J]. 中国药物警戒, 2025, 22(2): 188-192.
[4]	张美微, 李可千, 姚克宇, 朱彦. 中成药说明书功能表述现状及建议[J]. 中国药物警戒, 2025, 22(2): 193-196.
[5]	邵波, 钟露苗, 成雨竹, 邓华, 朱兰. 银黄口服制剂安全性风险分析及思考[J]. 中国药物警戒, 2025, 22(1): 84-87.
[6]	孟康康, 夏玉坤. 昂丹司琼制剂安全性风险分析[J]. 中国药物警戒, 2024, 21(9): 1034-1038.
[7]	邵波, 郭晓昕. 中药药物警戒回顾与思考[J]. 中国药物警戒, 2024, 21(7): 741-745.
[8]	刘翠丽, 吴晨, 王涛. 吡拉西坦制剂安全性风险分析及思考[J]. 中国药物警戒, 2024, 21(5): 563-566.
[9]	刘洁, 张建民, 张晓朦, 刘芳, 宋远, 钟旭丽. 某院中成药说明书的儿科用药风险分析与管理思考[J]. 中国药物警戒, 2024, 21(4): 422-427.
[10]	张建, 方慧华. 某院活血化瘀类中药注射剂使用评价标准建立的探索[J]. 中国药物警戒, 2024, 21(2): 185-189.
[11]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[12]	孟康康, 汤韧. 羟苯磺酸钙口服制剂上市后安全性分析[J]. 中国药物警戒, 2024, 21(11): 1288-1292.
[13]	刘小会, 周莉, 赵一鸣, 李英, 吴喜蓉, 王晓玲, 徐保平. 含右美沙芬成分药品说明书的成瘾性提示分析[J]. 中国药物警戒, 2024, 21(11): 1299-1302.
[14]	熊玮仪, 任经天. 抗肿瘤药说明书安全性信息上市后修订的考虑要点[J]. 中国药物警戒, 2024, 21(1): 94-97.
[15]	杨乐, 夏东胜, 王涛. 维生素B₆注射剂安全性风险分析[J]. 中国药物警戒, 2023, 20(7): 791-794.

静脉注射剂说明书给药途径描述的分析

Routes of Administration Described in Specifications of 236 Types of Intravenous Injections

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics